Progressive Care Inc (RXMD)

[Crumbster]

MIAMI , Aug. 22, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced that its wholly owned subsidiary PharmCo, LLC has met all three of the performance measures evaluated by Humana Inc., a leading health and well-being company, as part of its Rx Quality Network program. As a result of PharmCo’s performance scores in the first measurement period, the company will receive the maximum payout offered by Humana as part of the program’s rewards.

Provided by Humana Pharmacy Solutions, a division of Humana Inc., the Rx Quality Network focuses on the health outcomes of patient care related to medication adherence, in addition to rewarding pharmacies for adherence performance. The program aims to partner with participating pharmacies to improve member adherence in targeted drug classes, which may result in higher-quality care. The quality-based network rewards pharmacies on performance and establishes their pharmacy in-network/preferred for PDP/MAPD plans.

“We are very proud of the performance scores PharmCo Pharmacy received as part of Humana’s Rx Quality Network program. These scores are a testament to the quality of care we offer patients,” said S. Parikh Mars, Chief Executive Officer of Progressive Care Inc. “It is our hope that, as a result of consistently strong adherence results, physicians contracted with Humana will continue to lean on PharmCo as a trusted, high-quality provider. We believe that our success with initiatives like this one will lead to more opportunities for growth and allow us to provide even more patients with Progressive Care’s adherence packaging, proactive engagement model and pharmacological expertise.”

PharmCo Pharmacy received the following performance scores for the months of January 2018 – June 2018:
http://www.globenewswire.com/NewsRoom/AttachmentNg/84fcec5e-d689-48c5-a388-34e655a6d6ec

The first measurement period is January through June of each calendar year and the second period is January through December of each calendar year. Performance used for these measurement periods will be displayed in EQuIPP in August and February, respectively, due to the data refresh cycles. Humana will pay each participating pharmacy 50 percent of the performance payment calculated with respect to the January through June measurement period after the calculation for that measurement period. This payment amount will be deducted from the performance payment calculated for the second measurement period of January through December (full year calculation), which will be paid after the calculation for that measurement period.

The following targeted drug classes are directly tied to the Centers for Medicare & Medicaid Services Part D Stars adherence measures:

Diabetes Medications: Non-insulin diabetes medications (including biguanides, sulfonylureas, DPP-IV inhibitors, TZDs, incretin mimetics, meglitinides and SGLT2 inhibitors)
Hypertension Medications: Renin angiotensin system (RAS) antagonists (including ACE inhibitors, ARBs and direct renin inhibitors)
Cholesterol Medications: Statins
Progressive Care continues to make advances in becoming a leader in personalized healthcare and tele-pharmacy services through its many efforts to expand and educate its network. Earlier this month, Progressive Care earned its LegitScript certification verifying PharmCo Pharmacy to be a safe and credible online health resource. The company also recently launched DischargeRx, a new program designed to improve engagement between hospitals and patients, designed to help hospitals like Westchester General provide the best transitional care to its patients, while still preserving hospital resources.

Go to Humana.com/Pharmacy to learn more about Humana Pharmacy Solutions and its Rx Quality Network program.